Eradivir is a biotech company that aims to develop a non-immunological targeting agent for use against the virus that causes COVID-19.
Eradivir has raised $9.8M in total funding. The most recent round was Series A. The last funding was announced in September 2024.
Eradivir's investors include National Science Foundation, Biomedical Advanced Research and Development Authority (BARDA), Philip Low.
Eradivir is headquartered in West Lafayette, United States.
Eradivir is a biotech company that aims to develop a non-immunological targeting agent for use against the virus that causes COVID-19.
Eradivir is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Eradivir — Funding & Investors." VCBacked, September 23, 2024, https://www.vcbacked.co/company/eradivir. Accessed August 1, 2026.
VCBacked. (2024). Eradivir — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/eradivir
{{cite web |title=Eradivir — Funding & Investors |url=https://www.vcbacked.co/company/eradivir |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated